Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of brusatol in preparing medicament for preventing or/and treating inflammatory diseases

A technology of brucea brucea and inflammatory diseases, which is applied in the field of application of brucea brucea in the preparation of drugs for the prevention or treatment of inflammatory diseases, and can solve gastrointestinal irritation, pigmentation, complex pathogenesis of psoriasis, etc. problem, to achieve the effect of less toxic and side effects, lower expression level, and clear therapeutic mechanism

Inactive Publication Date: 2020-05-22
CHONGQING UNIV
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complex pathogenesis of psoriasis, various treatments are more or less limited
Such as external use of glucocorticoids, long-term use can cause adverse reactions such as skin atrophy, pigmentation, and vasodilation; Prompt and more severe after relapse
Systemic therapy Immunosuppressants represent the drug methotrexate, which can cause side effects such as gastrointestinal irritation, bone marrow suppression, and aplastic anemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of brusatol in preparing medicament for preventing or/and treating inflammatory diseases
  • Application of brusatol in preparing medicament for preventing or/and treating inflammatory diseases
  • Application of brusatol in preparing medicament for preventing or/and treating inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Effects of different concentrations of BR on the viability of HaCaT cells

[0042] After HaCaT cells were treated with 0, 10, 20, 40, 80, 160, and 320 nM BR for 24 h, cell viability was detected by MTS.

[0043] ① Cell inoculation: HaCaT cells in the logarithmic growth phase were digested with trypsin, centrifuged and resuspended, and the cells were plated into 96-well plates at 5000 cells / well. Put it in 37°C, 5% CO 2 12h in culture.

[0044] ②Drug treatment: Remove the medium, add 100 μL of different concentrations of Brucea Brucea to the 96-well plate, carry out 5 technical replicates for each concentration, and culture in the incubator for 24 hours.

[0045] ③ MTS experiment: Cell culture medium and CellTiter AQueous One Solution Cell Proliferation Assay (MTS) was mixed at a ratio of 10:1 in the dark. Add 100 μL of the mixture to each well and continue to incubate for 2 h.

[0046] ④Viability detection: read the absorbance value (OD value) of each well of cell...

Embodiment 2

[0049] TNF-α was further used to construct a psoriasis-like inflammatory proliferative cell model, and HaCaT cells were co-cultured with BR and TNF-α (20ng / mL) at three different concentrations of 20nM, 40nM, and 80nM for 24h, 48h, and 72h. Such as figure 2 As shown, the results showed that under the stimulation of TNF-α alone, the proliferation of HaCaT cells would be significantly accelerated, and when BR was co-cultured with TNF-α, BR could significantly reduce the abnormal proliferation of HaCaT cells caused by TNF-α, and It is time- and dose-dependent. The results are shown as the mean ± standard deviation of three independent experiments, *P<0.05, **P<0.01, ***P<0.001, ns means no statistical difference.

Embodiment 3

[0051] In order to further explore the potential mechanism of bruceicol inhibiting TNF-α-induced HaCaT cell proliferation, the changes of cell cycle under different treatment conditions were detected by flow cytometry. as image 3 as shown, image 3 In A is the flow cell cycle diagram, B is the percentage of cell cycle distribution, the results are shown as the mean ± standard deviation of three independent experiments, *P<0.05, **P<0.01 and ***P<0.001, ns means no statistical difference.

[0052] Depend on image 3 The results showed that in the group treated with TNF-α alone, the proportion of cells in S phase reached 45.17±3.56%, significantly higher than 40.49±2.88% of the control group, with a significant difference (P<0.05), when TNF-α When the cells were co-cultured with 20nM, 40nM, and 80nM bruceicol, the proportions of cells in S phase in each group were 41.56±2.03%, 36.59±4.64%, and 30.44±2.79%, respectively. Compared with the TNF-α group, each group had a signif...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of a traditional Chinese medicine component brusatol in preparing a medicament for preventing or / and treating inflammatory diseases, and in particular to an application of the brusatol in preparing a medicament for preventing or / and treating psoriasis. According to the invention, the brusatol is applied to medicament for treating related diseases to inhibita signal transduction pathway of NF-kappa B, so that overexpression of cytokines such as IL-6, IL-8, IL-1beta, IL-1alpha, TNF-alpha, ICAM-1 and the like can be obviously reduced. According to the invention, inflammatory reactions of skins are improved, the skin lesion degree is reduced, and symptoms such as erythema, scale, and infiltration of skins are relieved, so that the epidermis layer is relatively complete and the thickness of skin lesion is reduced.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to the application of Brucea Brucea in the preparation of drugs for preventing or treating inflammatory diseases. Background technique [0002] Psoriasis, commonly known as psoriasis, is a common chronic, relapsing, inflammatory skin disease. The clinical manifestations are mainly erythema and scales, with clear borders of the skin lesions, and the accumulation of scales can be higher than the skin surface. It is often found on the scalp and joints of the extremities, and in severe cases, it can spread to the skin of the whole body. Its course of disease is long, easy to relapse, and some cases are almost unhealed for life, and accompanied by multiple complications such as hypertension, diabetes, and cardiovascular disease. This disease is obstinate and intractable, has a strong impact on the patient's quality of life, and brings great harm to the patient's body and mind. Severe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P17/06A61P19/02A61P29/00A61P11/00
CPCA61K31/366A61P17/06A61P19/02A61P29/00A61P11/00
Inventor 蒋雪梅杨星罗洋邓博文
Owner CHONGQING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com